Investigational Oral Sleep Drug Boosts Deep Sleep in Animal Studies

How the Drug Alters Sleep Architecture

A new oral compound aimed at treating insomnia has shown promising results in preclinical trials, increasing total sleep time primarily through enhanced non‑rapid eye movement (NREM) sleep. The data were released by a research team that has been studying the drug’s effects in laboratory rodents and non‑human primates. The studies, conducted over the past year, suggest the compound could offer a more natural sleep profile than current hypnotics.

The research team, based at a leading university, administered the drug orally to mice and monkeys. In both species, treated animals slept significantly longer than controls, with the most pronounced gains occurring during the deep NREM phase. The compound’s mechanism appears to modulate specific neurotransmitter pathways involved in sleep regulation, although the exact targets remain under investigation. Early safety assessments indicate no major adverse effects at therapeutic doses.

Could This Offer a Safer Alternative to Benzodiazepines?

The investigators measured sleep stages using electroencephalography (EEG) and electromyography (EMG). Treated mice spent 25% more time in stage N3, the deepest sleep phase, compared to placebo. In primates, the drug increased total sleep duration by 18% and reduced the number of nighttime awakenings. These changes were achieved without increasing the overall amount of rapid eye movement (REM) sleep, a common side effect of many sleep aids. The researchers attribute this balance to the drug’s selective action on GABAergic receptors that are more active during NREM cycles.

„By targeting the pathways that drive deep sleep, we see a cleaner sleep profile,” said the lead scientist. „Patients often report feeling more rested, and that’s what our data suggest could happen with this compound.”

What Happens Next in Development?

Current hypnotics, such as benzodiazepines and non‑benzodiazepine sedatives, can disrupt sleep architecture and cause next‑day sedation. The new drug’s selective enhancement of NREM sleep may reduce these risks. Preliminary pharmacokinetic studies show a half‑life of roughly six hours, allowing once‑daily dosing and minimizing accumulation. Moreover, the compound did not produce tolerance or withdrawal symptoms in the animal models after repeated administration.

While the data are encouraging, the researchers caution that human trials are necessary to confirm efficacy and safety. The company plans to file for an investigational new drug application later this year, aiming to initiate Phase I studies in healthy volunteers by mid‑2027.

The next step involves scaling up production and conducting a single‑ascending dose study in humans. The team will monitor sleep patterns using polysomnography and assess daytime functioning. If Phase I results mirror the preclinical findings, the drug could enter Phase II trials focused on patients with chronic insomnia. The company’s goal is to provide a medication that restores natural sleep cycles without the drawbacks of current options.

Frequently Asked Questions

The potential impact on the sleep‑medicine market is significant. A drug that selectively boosts deep sleep could improve quality of life for millions of people suffering from insomnia, especially those who are sensitive to the side effects of existing treatments.

Q: When might patients see this drug on the market? A: If Phase I and II trials succeed, the drug could reach the market around 2030, subject to regulatory approval and additional studies.